February 12, 2019
Boehringer, IBM to test blockchain technology can help in clinical trials
Canadian Boehringer Ingelheim and IBM Canada want to find out how blockchain technology can help in clinical trials, the Boehringer…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 12, 2019
ReGenTree, Ora in mutual clinical study drug to treat dry eye syndrome
ReGenTree and Ora will mutually start testing the ReGenTree’s new drug RGN-259 for the treatment of dry eye syndrome, in a clinical study named ARISE-3, based entirely on the results of a previous clinical trials, ARISE-1 and ARISE-2.
February 12, 2019
Recipharm names new USA and Canada business manager
Recipharm, the contract development and manufacturing organisation (CDMO), has appointed a new director of business management for the USA and Canada, the company said in a press release on Tuesday.
February 11, 2019
Visualizing DNA Repair Proteins with the FV3000 Confocal Microscope
The FV3000 microscope from Olympus has allowed Dr. JaeJin Kim and others in the Miller lab to generate DNA damage using laser-microirradiation and study DNA damage response factor behavior both in fixed and live cells.
February 11, 2019
Immunicium to treat cancer patients with its lead in-development-product, ILIAD
Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.
February 8, 2019
Basilea nets milestone payment from Pfizer for Cresemba sales in Europe
Basilea Pharmaceutica cahsed $5 million from Pfizer’s milestone payment triggered for selling of the antifungal Cresemba in Europe..
February 7, 2019
Pulmatrix to start phase two testing Pulmazole in certain asthma patients
Pulmatrix can now begin to test in second phase its anti-fungal drug itraconaole inhaled iSPERSE formulation, to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, after the US FDA approved the company’s Investigational New Drug (IND) Application.
February 7, 2019
Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke
Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke, the company said in a statement, through an endothelin (ETB receptor) based mechanism of action, of anti-apoptosis and stimulation of hidden stem cells to repair the damaged brain by formation of new neurons and blood vessels.
February 7, 2019
Innovent can test its protein in patients with hemaological and advanced solid tumors
Innovent Biologics got approval from the National Medical Products Administration (NMPA) to start clinical trials for its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), in patients with hematological and advanced solid tumors.
February 7, 2019
NanoViricides names new Executive leader amid CEO resignation for personal reasons
NanoViricides confirmed in a statement that its CEO, Dr. Irach Taraporewala has resigned effective January 31, 2019, for personal reasons, and will continue as a Consultant to help the company with its regulatory advance as needed. The Board has promoted current President and Board Chairman, Dr. Anil Diwan, to Executive Chairman.